Skip to content

In the BioHarmony Drug Report Database


Kepivance (palifermin) is a protein pharmaceutical. Palifermin was first approved as Kepivance on 2004-12-15. It is used to treat mucositis in the USA. The pharmaceutical is active against fibroblast growth factor receptor 2.
Trade Name Kepivance
Common Name Palifermin
Indication mucositis
Drug Class Growth factors: fibroblast growth factors
Get full access now